Development of a New Magnetometer for Sentinel Lymph Node Mapping Designed for Video-Assisted Thoracic Surgery in Non–Small Cell Lung Cancer

Background. We previously developed a method for sentinel lymph node (SLN) mapping in non–small cell lung cancer (NSCLC), based on the magnetic force produced by a magnetite tracer already approved for use as a contrast material for magnetic resonance imaging. However, it is difficult to use that te...

Full description

Saved in:
Bibliographic Details
Published in:Surgical innovation 2015-08, Vol.22 (4), p.401-405
Main Authors: Imai, Kazuhiro, Kawaharada, Yasushi, Ogawa, Jun-ichi, Saito, Hajime, Kudo, Satoshi, Takashima, Shinogu, Saito, Yoshitaro, Atari, Maiko, Ito, Aki, Terata, Kaori, Yoshino, Kei, Sato, Yusuke, Motoyama, Satoru, Minamiya, Yoshihiro
Format: Article
Language:English
Subjects:
Aged
Carcinoma, Non-Small-Cell Lung - surgery
Equipment Design
Ferrosoferric Oxide - therapeutic use
Humans
Lung Neoplasms - surgery
Magnetometry - instrumentation
Middle Aged
Sentinel Lymph Node Biopsy - instrumentation
Sentinel Lymph Node Biopsy - methods
Thoracic Surgery, Video-Assisted - instrumentation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. We previously developed a method for sentinel lymph node (SLN) mapping in non–small cell lung cancer (NSCLC), based on the magnetic force produced by a magnetite tracer already approved for use as a contrast material for magnetic resonance imaging. However, it is difficult to use that technique with video-assisted thoracic surgery (VATS) because the sensing element of the magnetometer is large and thick. The purpose of the present study was to develop a smaller, thinner VATS-compatible magnetometer. Methods. The tracer employed was Ferucarbotran, a colloidal solution of superparamagnetic iron oxide coated with carbodextran. Fifteen patients with clinical stage I NSCLC were enrolled, and each received 1.6 mL of Ferucarbotran, injected intraoperatively at 5 points around the tumor. The magnetic force within the sampling lymph nodes was measured using the new VATS-compatible magnetometer. Results. SLNs were detected in 11 (73.3%) of the 15 patients using the VATS-compatible magnetometer. The average number of SLNs identified per patient was 1.8 (range 0-4). No complications related to the SLN detection method were observed. Conclusions. The new VATS-compatible magnetometer appears to have substantial advantages over techniques using a radioisotope and our earlier magnetometer, as it can be inserted through the small VATS port site.
ISSN:1553-3506
1553-3514
DOI:10.1177/1553350615585421